Kelly Thomas Patrick 4
4 · Xenon Pharmaceuticals Inc. · Filed Oct 17, 2025
Insider Transaction Report
Form 4
Kelly Thomas Patrick
Chief Financial Officer
Transactions
- Award
Restricted Share Units
2025-10-15+30,000→ 30,000 totalExercise: $0.00→ Common Shares (30,000 underlying) - Award
Share Option (Right to Buy)
2025-10-15+225,000→ 225,000 totalExercise: $41.90Exp: 2035-10-14→ Common Shares (225,000 underlying)
Footnotes (2)
- [F1]Vesting 25% on October 15, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
- [F2]Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on October 15, 2026.